125 related articles for article (PubMed ID: 38193270)
1. Proteomic analysis of extracellular vesicle cargoes mirror the cardioprotective effects of rivaroxaban in patients with venous thromboembolism.
Weiss L; Uhrig W; Kelliher S; Szklanna PB; Prendiville T; Comer SP; Edebiri O; Egan K; Lennon Á; Kevane B; Murphy S; Ní Áinle F; Maguire PB
Proteomics Clin Appl; 2024 Jan; ():e2300014. PubMed ID: 38193270
[TBL] [Abstract][Full Text] [Related]
2. Nonvalvular atrial fibrillation patients anticoagulated with rivaroxaban compared with warfarin exhibit reduced circulating extracellular vesicles with attenuated pro-inflammatory protein signatures.
Weiss L; Keaney J; Szklanna PB; Prendiville T; Uhrig W; Wynne K; Kelliher S; Ewins K; Comer SP; Egan K; O'Rourke E; Moran E; Petrov G; Patel A; Lennon Á; Blanco A; Kevane B; Murphy S; Ní Áinle F; Maguire PB
J Thromb Haemost; 2021 Oct; 19(10):2583-2595. PubMed ID: 34161660
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
[TBL] [Abstract][Full Text] [Related]
4. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
Perales IJ; San Agustin K; DeAngelo J; Campbell AM
Ann Pharmacother; 2020 Apr; 54(4):344-350. PubMed ID: 31672028
[No Abstract] [Full Text] [Related]
5. Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism.
Arachchillage DR; Mackie IJ; Efthymiou M; Chitolie A; Hunt BJ; Isenberg DA; Khamashta M; Machin SJ; Cohen H
J Thromb Haemost; 2016 Nov; 14(11):2177-2186. PubMed ID: 27541499
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
Rollins BM; Silva MA; Donovan JL; Kanaan AO
Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
[TBL] [Abstract][Full Text] [Related]
7. Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism.
Robertson L; Yeoh SE; Ramli A
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011088. PubMed ID: 29244199
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.
Larsen TB; Skjøth F; Kjældgaard JN; Lip GYH; Nielsen PB; Søgaard M
Lancet Haematol; 2017 May; 4(5):e237-e244. PubMed ID: 28411120
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state.
Coleman CI; Turpie AGG; Bunz TJ; Baker WL; Beyer-Westendorf J
Thromb Res; 2018 Mar; 163():132-137. PubMed ID: 29407625
[TBL] [Abstract][Full Text] [Related]
10. Oral anticoagulation therapy and subsequent risk of venous thromboembolism in atrial fibrillation patients.
Lutsey PL; Norby FL; Zakai NA; MacLehose RF; Chen LY; Shah S; Datta YH; Alonso A
Curr Med Res Opin; 2019 May; 35(5):837-845. PubMed ID: 30362847
[TBL] [Abstract][Full Text] [Related]
11. Recurrent thromboembolism, bleeding, and mortality in Asian patients with venous thromboembolism receiving different oral anticoagulants: A nationwide analysis.
Lee MC; Liao CT; Feng IJ; Yu T; Chang WT; Shih MF; Su HC; Toh HS
Medicine (Baltimore); 2022 Sep; 101(37):e30412. PubMed ID: 36123930
[TBL] [Abstract][Full Text] [Related]
12. Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costs.
Spyropoulos AC; Ashton V; Chen YW; Wu B; Peterson ED
Thromb Res; 2019 Oct; 182():159-166. PubMed ID: 31493618
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data.
Costa OS; Beyer-Westendorf J; Ashton V; Milentijevic D; Moore KT; Bunz TJ; Coleman CI
J Thromb Thrombolysis; 2021 Feb; 51(2):349-358. PubMed ID: 32588288
[TBL] [Abstract][Full Text] [Related]
14. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
J Med Econ; 2015 Jun; 18(6):399-409. PubMed ID: 25586203
[TBL] [Abstract][Full Text] [Related]
15. Rivaroxaban Versus Warfarin for Management of Obese African Americans With Non-Valvular Atrial Fibrillation or Venous Thromboembolism: A Retrospective Cohort Analysis.
Costa OS; Beyer-Westendorf J; Ashton V; Milentijevic D; Moore KT; Bunz TJ; Coleman CI
Clin Appl Thromb Hemost; 2020; 26():1076029620954910. PubMed ID: 33085526
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
Coleman CI; Bunz TJ; Turpie AGG
Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
[TBL] [Abstract][Full Text] [Related]
17. Health Economic Analysis of Rivaroxaban and Warfarin for Venous Thromboembolism Management in Chinese Patients.
Fung KP; Chan KH; Ng V; Tsui PT; You JHS
Cardiovasc Drugs Ther; 2019 Jun; 33(3):331-337. PubMed ID: 30888571
[TBL] [Abstract][Full Text] [Related]
18. Low persistence to rivaroxaban or warfarin among patients with new venous thromboembolism at a safety net academic medical center.
Patel SM; Wang T; Outler DL; Elliott J; Knauss M; Peasah SK; Akbashev M
J Thromb Thrombolysis; 2020 Feb; 49(2):287-293. PubMed ID: 31598931
[TBL] [Abstract][Full Text] [Related]
19. Comparative outcomes associated with rivaroxaban versus warfarin use in elderly patients with atrial fibrillation or acute venous thromboembolism managed in the United States: a systematic review of observational studies.
Baker WL; Roberts MS; Bessada Y; Caroti KS; Ashton V; Bookhart BK; Coleman CI
Curr Med Res Opin; 2023 Sep; 39(9):1183-1194. PubMed ID: 37584187
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness, safety, and healthcare costs associated with rivaroxaban versus warfarin among venous thromboembolism patients with obesity: a real-world study in the United States.
Berger JS; Laliberté F; Kharat A; Lejeune D; Moore KT; Jung Y; Lefebvre P; Ashton V
J Thromb Thrombolysis; 2022 Oct; 54(3):438-448. PubMed ID: 35562510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
